Markus Maulhardt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Markus Maulhardt has a total of 206 co-authors. Here are the top co-authors by number of shared publications:
- Evgenii Shumilov
Department of Medicine A, Hematology, Oncology and Pneumology University Hospital Muenster Muenster Germany
6 shared publications Enver Aydilek
16Department of Hematology and Medical Oncology, University Hospital Goettingen, Goettingen, Germany
5 shared publicationsGeorg Lenz
Department of Medicine A - Hematology, Hemostaseology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany
4 shared publicationsJustin Hasenkamp
Department of Hematology and Medical Oncology, University Medical Center Goettingen
4 shared publications- Bastian von Tresckow
Department of Hematology and Stem Cell Transplantation, West German Cancer Center and German Cancer Consortium (DKTK partner site Essen), University Hospital Essen, University of Duisburg-Essen, Essen, Germany
3 shared publications Gerald Wulf
3 shared publications
Latest Publications
- 24 November 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (22) , 7751-7766
Loncastuximab tesirine in heavily pretreated patients with large B-cell lymphoma: a German Lymphoma Alliance analysis
Few treatment options remain for patients with large B-cell lymphoma progressing after multiple lines of therapy, including the new CD19-directed antibody-drug conjugate loncastuximab tesirine (lonca). To further elucidate its efficacy and safety, we conducted a real-world analysis including data from 31 German centers. Ninety-three heavily pretreated patients received lonca in the third and later lines of therapy. Seventy-six percent had received treatment with chimeric antigen receptor T cells (n = 55), bispecific antibodies (n = 56), or both (n = 40). The overall response rate was 27%, and complete response rate was 10%. Median progression-free survival (mPFS) and median overall survival (mOS) were 2.2 and 4.4 months, respectively. The mPFS of responders was 11.4 months. Toxicity was acceptable, with grade ≥3 infections (in 13% of patients) being the most common adverse event. Patients receiving subsequent allogeneic stem cell transplantation survived significantly longer than the remaining nonconsolidated patients (mOS: 15.2 vs 3.8 months; P = .048). In multivariable analysis, no response to the last therapy before lonca (OS: hazard ratio [HR], 2.5; P = .014) and secondary International Prognostic Index (PFS/OS: HR, ≥2.0; P ≤ .024) were significantly associated with poor outcomes. Lonca demonstrated a favorable safety profile with moderate efficacy in heavily pretreated patients. Along with enabling timely access to subsequent therapy, efficacy in earlier lines with combination partners may further increase response rates and durability of response.
- 24 November 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (22) , 7751-7766
Loncastuximab tesirine in heavily pretreated patients with large B-cell lymphoma: a German Lymphoma Alliance analysis
Few treatment options remain for patients with large B-cell lymphoma progressing after multiple lines of therapy, including the new CD19-directed antibody-drug conjugate loncastuximab tesirine (lonca). To further elucidate its efficacy and safety, we conducted a real-world analysis including data from 31 German centers. Ninety-three heavily pretreated patients received lonca in the third and later lines of therapy. Seventy-six percent had received treatment with chimeric antigen receptor T cells (n = 55), bispecific antibodies (n = 56), or both (n = 40). The overall response rate was 27%, and complete response rate was 10%. Median progression-free survival (mPFS) and median overall survival (mOS) were 2.2 and 4.4 months, respectively. The mPFS of responders was 11.4 months. Toxicity was acceptable, with grade ≥3 infections (in 13% of patients) being the most common adverse event. Patients receiving subsequent allogeneic stem cell transplantation survived significantly longer than the remaining nonconsolidated patients (mOS: 15.2 vs 3.8 months; P = .048). In multivariable analysis, no response to the last therapy before lonca (OS: hazard ratio [HR], 2.5; P = .014) and secondary International Prognostic Index (PFS/OS: HR, ≥2.0; P ≤ .024) were significantly associated with poor outcomes. Lonca demonstrated a favorable safety profile with moderate efficacy in heavily pretreated patients. Along with enabling timely access to subsequent therapy, efficacy in earlier lines with combination partners may further increase response rates and durability of response.
- Open Access
- 4 October 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (10) , e72341
Extranodal Organ Involvement in Chronic Lymphocytic Leukemia: Clinical Features and Outcomes With Bruton Tyrosine Kinase and BCL ‐2 Inhibitors
Background: Although chronic lymphocytic leukemia (CLL) typically follows an indolent course involving blood, lymph nodes, and bone marrow, extranodal organ involvement is rare and poorly characterized. Methods: We retrospectively analyzed 19 patients with histologically confirmed extranodal CLL or small lymphocytic lymphoma (SLL), assessing organ involvement, clinical features, genetic risk factors, and response to therapy. Results: Different organs were affected, most frequently the kidneys (7/19). Median age at initial CLL diagnosis was 54 years, median time from CLL diagnosis to extranodal manifestation was 3 years. Genetic risk factors were comparable to typical CLL cohorts. Per treatment episode, exploratory overall response rate (ORR) for Bruton tyrosine kinase inhibitors (BTKi) was 88.9% (8/9); median progression‐free survival (PFS) from treatment initiation was 29 months. For venetoclax‐based regimens, ORR was 83.3% (5/6) and median PFS 52 months. Conclusions: These data suggest meaningful activity of BTK and BCL‐2 inhibitors in CLL/SLL with extranodal organ involvement.
- 4 October 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (10) , e72341
Open AccessExtranodal Organ Involvement in Chronic Lymphocytic Leukemia: Clinical Features and Outcomes With Bruton Tyrosine Kinase and BCL ‐2 Inhibitors
Background: Although chronic lymphocytic leukemia (CLL) typically follows an indolent course involving blood, lymph nodes, and bone marrow, extranodal organ involvement is rare and poorly characterized. Methods: We retrospectively analyzed 19 patients with histologically confirmed extranodal CLL or small lymphocytic lymphoma (SLL), assessing organ involvement, clinical features, genetic risk factors, and response to therapy. Results: Different organs were affected, most frequently the kidneys (7/19). Median age at initial CLL diagnosis was 54 years, median time from CLL diagnosis to extranodal manifestation was 3 years. Genetic risk factors were comparable to typical CLL cohorts. Per treatment episode, exploratory overall response rate (ORR) for Bruton tyrosine kinase inhibitors (BTKi) was 88.9% (8/9); median progression‐free survival (PFS) from treatment initiation was 29 months. For venetoclax‐based regimens, ORR was 83.3% (5/6) and median PFS 52 months. Conclusions: These data suggest meaningful activity of BTK and BCL‐2 inhibitors in CLL/SLL with extranodal organ involvement.
- Open Access
- 25 September 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1887912
Allogeneic hematopoietic cell transplantation for therapy-related hematological malignancies in patients with multiple myeloma
Improved survival in multiple myeloma (MM) patients after high-dose chemotherapy, autologous hematopoietic cell transplantation (auto-HCT), and novel agents has led to an increasing incidence of therapy-related hematological malignancies (t-HM), although optimal management remains unclear, particularly the role of allogeneic HCT (allo-HCT). We conducted a retrospective single-center study of adult MM patients who underwent first auto-HCT between 2010 and 2025 and subsequently developed t-HM, analyzing clinical, molecular, cytogenetic features, treatment strategies, and outcomes, with a focus on allo-HCT. Among 519 patients, 23 (4.4%) developed t-HM, including therapy-related acute myeloid leukemia (43%), myelodysplastic syndrome (35%), and B-cell acute lymphoblastic leukemia (17%), with a median latency of 58.7 months after auto-HCT. High-risk genetics were common, including TP53 mutations in 52% and complex cytogenetics in 35%. Fourteen patients (61%) underwent allo-HCT, mainly with reduced-intensity conditioning. Median overall survival (OS) for the cohort was 31.5 months, while patients receiving allo-HCT had significantly superior OS compared with non-transplanted patients (median not reached vs. 2.5 months; P = 0.046). Therapy-related hematologic malignancies after MM treatment are uncommon but aggressive and genetically high-risk. In this cohort, allo-HCT was associated with improved survival and may represent a potentially curative approach in selected patients despite substantial toxicity.
- 25 September 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1887912
Open AccessAllogeneic hematopoietic cell transplantation for therapy-related hematological malignancies in patients with multiple myeloma
Improved survival in multiple myeloma (MM) patients after high-dose chemotherapy, autologous hematopoietic cell transplantation (auto-HCT), and novel agents has led to an increasing incidence of therapy-related hematological malignancies (t-HM), although optimal management remains unclear, particularly the role of allogeneic HCT (allo-HCT). We conducted a retrospective single-center study of adult MM patients who underwent first auto-HCT between 2010 and 2025 and subsequently developed t-HM, analyzing clinical, molecular, cytogenetic features, treatment strategies, and outcomes, with a focus on allo-HCT. Among 519 patients, 23 (4.4%) developed t-HM, including therapy-related acute myeloid leukemia (43%), myelodysplastic syndrome (35%), and B-cell acute lymphoblastic leukemia (17%), with a median latency of 58.7 months after auto-HCT. High-risk genetics were common, including TP53 mutations in 52% and complex cytogenetics in 35%. Fourteen patients (61%) underwent allo-HCT, mainly with reduced-intensity conditioning. Median overall survival (OS) for the cohort was 31.5 months, while patients receiving allo-HCT had significantly superior OS compared with non-transplanted patients (median not reached vs. 2.5 months; P = 0.046). Therapy-related hematologic malignancies after MM treatment are uncommon but aggressive and genetically high-risk. In this cohort, allo-HCT was associated with improved survival and may represent a potentially curative approach in selected patients despite substantial toxicity.
- Open Access
- 11 September 2026
- Published by Wiley in European Journal of Haematology
Transplantation Strategies in Treatment of Primary Plasma Cell Leukemia in Germany—A Multi‐Center Analysis
Objectives: Primary plasma cell leukemia (pPCL) is a rare disease with poor outcomes. As data on randomized phase‐III trials are lacking, treatment recommendations are predominately based on retrospective analyses incorporating time periods with outdated therapies. Thus, the optimal consolidation strategy remains to be defined. Methods: We conducted a retrospective, multi‐center analysis with 49 transplant‐eligible patients diagnosed with pPCL between 2011 and 2025 focusing on different stem cell transplantation (SCT) strategies as consolidation treatment in first remission: single autologous (auto) or single allogeneic (allo) SCT versus patients with tandem cell therapy strategies (auto‐auto, allo‐auto, auto‐chimeric antigen receptor therapy). Results: The median follow‐up after first SCT was 31 months. The cumulative incidence of initiating next treatment was lower after tandem cell therapy compared to single SCT (at 12 months: 42% vs. 57%, p = 0.006). Moreover, in a multivariable analysis incorporating cytogenetic risk and response to induction therapy, tandem transplantation strategies tended to be the only independent predictor for prolonged time to next treatment (TTNT, p = 0.077). Noteworthy, differences in TTNT between patients with a single SCT and patients with tandem cell therapy did not translate into an improved overall survival, possibly due to potent salvage therapies. Conclusions: Our data support recent recommendations advising treating patients with tandem transplantation regimes.
- 11 September 2026
- Published by Wiley in European Journal of Haematology
Open AccessTransplantation Strategies in Treatment of Primary Plasma Cell Leukemia in Germany—A Multi‐Center Analysis
Objectives: Primary plasma cell leukemia (pPCL) is a rare disease with poor outcomes. As data on randomized phase‐III trials are lacking, treatment recommendations are predominately based on retrospective analyses incorporating time periods with outdated therapies. Thus, the optimal consolidation strategy remains to be defined. Methods: We conducted a retrospective, multi‐center analysis with 49 transplant‐eligible patients diagnosed with pPCL between 2011 and 2025 focusing on different stem cell transplantation (SCT) strategies as consolidation treatment in first remission: single autologous (auto) or single allogeneic (allo) SCT versus patients with tandem cell therapy strategies (auto‐auto, allo‐auto, auto‐chimeric antigen receptor therapy). Results: The median follow‐up after first SCT was 31 months. The cumulative incidence of initiating next treatment was lower after tandem cell therapy compared to single SCT (at 12 months: 42% vs. 57%, p = 0.006). Moreover, in a multivariable analysis incorporating cytogenetic risk and response to induction therapy, tandem transplantation strategies tended to be the only independent predictor for prolonged time to next treatment (TTNT, p = 0.077). Noteworthy, differences in TTNT between patients with a single SCT and patients with tandem cell therapy did not translate into an improved overall survival, possibly due to potent salvage therapies. Conclusions: Our data support recent recommendations advising treating patients with tandem transplantation regimes.
- Open Access
- 18 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1783-1796
Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS‐like tyrosine kinase 3 ( FLT3 )‐mutated acute myeloid leukaemia patients: A multicentre real‐world study
Summary: Patients with relapsed or refractory acute myeloid leukaemia (r/r AML) harbouring FMS‐like tyrosine kinase 3 (FLT3) mutations generally have poor prognosis and limited treatment options. The second‐generation FLT3 inhibitor gilteritinib provides better disease control compared to standard relapse therapies and was approved based on two randomized trials. We analysed its efficacy and safety in a real‐world cohort of r/r AML patients undergoing gilteritinib treatment including allogeneic haematopoietic stem cell transplantation (alloHSCT). Data were collected from all consecutive r/r AML patients with FLT3‐internal tandem duplication and/or FLT3‐tyrosine kinase domain mutations receiving gilteritinib at 25 centres. Response and survival were analysed using descriptive and correlative statistics. A total of 156 patients were analysed, 55.1% with relapse after previous alloHSCT, and 46.2% with prior FLT3 inhibitor exposure. The overall complete remission/incomplete remission (CR/Cri) rate was 45.3%, with a median overall survival (OS) of 10.0 months. Patients receiving gilteritinib only had a 1‐year OS of 34%, while those with consolidating alloHSCT had a 1‐year OS of 76%–92%, depending on gilteritinib maintenance post‐transplant. Resuming gilteritinib post‐transplant led to an 85.7% CR/CRi rate. Our real‐world data confirm that gilteritinib is an effective single‐agent therapy for r/r AML with FLT3 mutations, with best outcomes when used as a bridge to transplant and post‐transplant maintenance.
- 18 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1783-1796
Open AccessTreatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS‐like tyrosine kinase 3 ( FLT3 )‐mutated acute myeloid leukaemia patients: A multicentre real‐world study
Summary: Patients with relapsed or refractory acute myeloid leukaemia (r/r AML) harbouring FMS‐like tyrosine kinase 3 (FLT3) mutations generally have poor prognosis and limited treatment options. The second‐generation FLT3 inhibitor gilteritinib provides better disease control compared to standard relapse therapies and was approved based on two randomized trials. We analysed its efficacy and safety in a real‐world cohort of r/r AML patients undergoing gilteritinib treatment including allogeneic haematopoietic stem cell transplantation (alloHSCT). Data were collected from all consecutive r/r AML patients with FLT3‐internal tandem duplication and/or FLT3‐tyrosine kinase domain mutations receiving gilteritinib at 25 centres. Response and survival were analysed using descriptive and correlative statistics. A total of 156 patients were analysed, 55.1% with relapse after previous alloHSCT, and 46.2% with prior FLT3 inhibitor exposure. The overall complete remission/incomplete remission (CR/Cri) rate was 45.3%, with a median overall survival (OS) of 10.0 months. Patients receiving gilteritinib only had a 1‐year OS of 34%, while those with consolidating alloHSCT had a 1‐year OS of 76%–92%, depending on gilteritinib maintenance post‐transplant. Resuming gilteritinib post‐transplant led to an 85.7% CR/CRi rate. Our real‐world data confirm that gilteritinib is an effective single‐agent therapy for r/r AML with FLT3 mutations, with best outcomes when used as a bridge to transplant and post‐transplant maintenance.
- Open Access
- 7 August 2026
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (10) , 670-688.e2
In Search of Long-Term Disease Control: CAR T-Cell Therapy With Axicabtagene Ciloleucel or Allogeneic Hematopoietic Cell Transplantation Against Relapsed/Refractory Large B-Cell Lymphoma
- 7 August 2026
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (10) , 670-688.e2
Open AccessIn Search of Long-Term Disease Control: CAR T-Cell Therapy With Axicabtagene Ciloleucel or Allogeneic Hematopoietic Cell Transplantation Against Relapsed/Refractory Large B-Cell Lymphoma
- Open Access
- 30 June 2026
- Published by Elsevier in SSRN Electronic Journal
In Quest of Long-term Disease Control CAR T-cell Therapy with Axicabtagene ciloleucel or Allogeneic Hematopoietic Cell Transplantation against Relapsed/Refractory Large B-cell Lymphoma
Background: Large B-cell lymphoma (LBCL) remains challenging in the relapsed/refractory (r/r) setting. CD19-directed chimeric antigen receptor (CAR) T-cell therapy has become the preferred cellular immunotherapy, whereas allogeneic hematopoietic cell transplantation (allo-HCT) remains a salvage option. Comparative real-world data are limited.Patients and Methods: We retrospectively analyzed 187 patients with r/r LBCL treated with either allo-HCT or axicabtagene ciloleucel (axi-cel) at a single center. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Secondary endpoints included relapse incidence (RI), non-relapse mortality (NRM), and treatment-related toxicities. Propensity score matching (PSM) was performed to adjust for baseline differences.Results: Response rates and RI were comparable between groups. However, NRM was significantly higher after allo-HCT than after axi-cel (36% vs. 12%; p<0.001), mainly due to infections and graft-versus-host disease. Consequently, axi-cel was associated with superior 12-month PFS (50.1% vs. 33.8%) and OS (60.5% vs. 43.2%; both p<0.05). These findings were confirmed in third-line-or-later and PSM analyses. Primary refractoriness and poor performance status independently predicted inferior outcomes. In patients with chemorefractory disease before cellular therapy, axi-cel provided significantly improved survival, whereas outcomes were comparable in patients with chemosensitive disease.Conclusion: Axi-cel provided superior survival compared with allo-HCT in r/r LBCL, primarily owing to lower treatment-related mortality and improved disease control in patients with chemorefractory disease.
- 30 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessIn Quest of Long-term Disease Control CAR T-cell Therapy with Axicabtagene ciloleucel or Allogeneic Hematopoietic Cell Transplantation against Relapsed/Refractory Large B-cell Lymphoma
Background: Large B-cell lymphoma (LBCL) remains challenging in the relapsed/refractory (r/r) setting. CD19-directed chimeric antigen receptor (CAR) T-cell therapy has become the preferred cellular immunotherapy, whereas allogeneic hematopoietic cell transplantation (allo-HCT) remains a salvage option. Comparative real-world data are limited.Patients and Methods: We retrospectively analyzed 187 patients with r/r LBCL treated with either allo-HCT or axicabtagene ciloleucel (axi-cel) at a single center. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Secondary endpoints included relapse incidence (RI), non-relapse mortality (NRM), and treatment-related toxicities. Propensity score matching (PSM) was performed to adjust for baseline differences.Results: Response rates and RI were comparable between groups. However, NRM was significantly higher after allo-HCT than after axi-cel (36% vs. 12%; p<0.001), mainly due to infections and graft-versus-host disease. Consequently, axi-cel was associated with superior 12-month PFS (50.1% vs. 33.8%) and OS (60.5% vs. 43.2%; both p<0.05). These findings were confirmed in third-line-or-later and PSM analyses. Primary refractoriness and poor performance status independently predicted inferior outcomes. In patients with chemorefractory disease before cellular therapy, axi-cel provided significantly improved survival, whereas outcomes were comparable in patients with chemosensitive disease.Conclusion: Axi-cel provided superior survival compared with allo-HCT in r/r LBCL, primarily owing to lower treatment-related mortality and improved disease control in patients with chemorefractory disease.
- Open Access
- 24 June 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (7) , 942
High-Dimensional Immunophenotyping of Plasma-Derived Small Extracellular Vesicles in Pancreatic Cancer: An Exploratory Proof-of-Principle Study
Pancreatic ductal adenocarcinoma (PDAC) is increasingly recognized as a systemic malignancy, characterized by profound alterations in tumor–host interactions. Small extracellular vesicles (sEVs) in peripheral blood may reflect these alterations and represent a promising minimally invasive source of biomarker information. In this proof-of-principle study, plasma-derived sEVs from patients with PDAC, healthy controls, and a comparative cohort with neuroendocrine lung cancer (NLC) were isolated by differential ultracentrifugation and characterized by western blotting and nanoparticle tracking analysis. Surface marker profiling was performed using the MACSPlex EV Kit IO, followed by univariate, multivariate, and machine-learning-based analyses. PDAC samples exhibited a distinct sEV immunophenotype with coordinated enrichment of angiogenesis-related markers (including CD105 and CD146), immune-regulatory markers (including CD25 and CD40), the coagulation-related marker CD142 and the invasion-associated marker MCSP. Principal component analysis, hierarchical clustering, and Random Forest classification showed exploratory separation of PDAC patients from healthy controls and NLC, supporting the presence of disease-specific vesicle surface marker patterns. In a very small subset of paired samples, descriptive longitudinal analyses illustrated measurable intra-individual changes during chemotherapy. Plasma sEV immunophenotyping is a technically feasible approach for capturing systemic disease-associated alterations in PDAC and provides a foundation for future biomarker-oriented validation studies.
- 24 June 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (7) , 942
Open AccessHigh-Dimensional Immunophenotyping of Plasma-Derived Small Extracellular Vesicles in Pancreatic Cancer: An Exploratory Proof-of-Principle Study
Pancreatic ductal adenocarcinoma (PDAC) is increasingly recognized as a systemic malignancy, characterized by profound alterations in tumor–host interactions. Small extracellular vesicles (sEVs) in peripheral blood may reflect these alterations and represent a promising minimally invasive source of biomarker information. In this proof-of-principle study, plasma-derived sEVs from patients with PDAC, healthy controls, and a comparative cohort with neuroendocrine lung cancer (NLC) were isolated by differential ultracentrifugation and characterized by western blotting and nanoparticle tracking analysis. Surface marker profiling was performed using the MACSPlex EV Kit IO, followed by univariate, multivariate, and machine-learning-based analyses. PDAC samples exhibited a distinct sEV immunophenotype with coordinated enrichment of angiogenesis-related markers (including CD105 and CD146), immune-regulatory markers (including CD25 and CD40), the coagulation-related marker CD142 and the invasion-associated marker MCSP. Principal component analysis, hierarchical clustering, and Random Forest classification showed exploratory separation of PDAC patients from healthy controls and NLC, supporting the presence of disease-specific vesicle surface marker patterns. In a very small subset of paired samples, descriptive longitudinal analyses illustrated measurable intra-individual changes during chemotherapy. Plasma sEV immunophenotyping is a technically feasible approach for capturing systemic disease-associated alterations in PDAC and provides a foundation for future biomarker-oriented validation studies.
- Open Access
- 3 June 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (14) , 5070-5073
Epcoritamab in Richter Transformation: Insights from a Real-World Case Series
- 3 June 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (14) , 5070-5073
Open AccessEpcoritamab in Richter Transformation: Insights from a Real-World Case Series
- Open Access
- 2 June 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1) , 88
Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysis
- 2 June 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1) , 88
Open AccessChimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysis